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Abstract
Background: Whole brain radiotherapy (WBRT) has been the treatment of choice for patients with brain metastases.
However, change/decline of neurocognitive functions (NCFs) resulting from impaired hippocampal neurogenesis
might occur after WBRT. It is reported that conformal hippocampal sparing would provide the preservation of NCFs.
Our study aims to investigate the hippocampal dosimetry and to demonstrate the correlation between hippocampal
dosimetry and neurocognitive outcomes in patients receiving hippocampal sparing during WBRT (HS-WBRT).
Methods: Forty prospectively recruited cancer patients underwent HS-WBRT for therapeutic or prophylactic
purposes. Before receiving HS-WBRT, all participants received a battery of baseline neurocognitive assessment,
including memory, executive functions and psychomotor speed. The follow-up neurocognitive assessment at
4 months after HS-WBRT was also performed. For the delivery of HS-WBRT, Volumetric Modulated Arc Therapy
(VMAT) with two full arcs and two non-coplanar partial arcs was employed. For each treatment planning,
dose volume histograms were generated for left hippocampus, right hippocampus, and the composite
hippocampal structure respectively. Biologically equivalent doses in 2-Gy fractions (EQD2) assuming an alpha/
beta ratio of 2 Gy were computed. To perform analyses addressing the correlation between hippocampal
dosimetry and the change in scores of NCFs, pre- and post-HS-WBRT neurocognitive assessments were
available in 24 patients in this study.
Results: Scores of NCFs were quite stable before and after HS-WBRT in terms of hippocampus-dependent memory.
Regarding verbal memory, the corresponding EQD2 values of 0, 10, 50, 80 % irradiating the composite hippocampal
structure with <12.60 Gy, <8.81, <7.45 Gy and <5.83 Gy respectively were significantly associated with neurocognitive
preservation indicated by the immediate recall of Word List Test of Wechsler Memory Scale-III. According to logistic
regression analyses, it was noted that dosimetric parameters specific to left sided hippocampus exerted an influence
on immediate recall of verbal memory (adjusted odds ratio, 4.08; p-value, 0.042, predicting patients’ neurocognitive
decline after receiving HS-WBRT).
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Conclusions: Functional preservation by hippocampal sparing during WBRT is indeed achieved in our study. Providing
that modern VMAT techniques can reduce the dose irradiating bilateral hippocampi below dosimetric threshold,
patients should be recruited in prospective trials of hippocampal sparing during cranial irradiation to accomplish
neurocognitive preservation while maintaining intracranial control.
Trial registration: Current Controlled Trials NCT02504788
Keywords: Brain metastasis, Whole brain radiotherapy, Neurocognitive functions, Hippocampus, Hippocampus sparing
during whole brain radiotherapy, Hippocampal dosimetry
Background
Brain metastasis is usually a dismal diagnosis affecting
200,000 Americans each year and up to 30 % of patients
with cancer [1]. Traditionally, whole brain radiation
(WBRT) with or without surgical resection has ever
been the treatment of choice for patients with solitary
brain metastasis and WBRT alone for those with mul-
tiple brain metastases; WBRT has long been a practical
therapeutic modality for various settings of management
in radiation oncology [2, 3]. For instance, the indications
for WBRT include overt brain metastasis/metastases, the
setting of prophylactic cranial irradiation (PCI) used for
patients with limited-stage small cell lung cancer, and
even some patients with extensive-stage small cell lung
cancer [4]. Although control of the metastatic brain le-
sion(s) by WBRT might be generally the most important
factor for stabilizing neurocognitive functions [5], para-
doxical decline in neurocognitive functions (NCFs) can
also occur as a sequel of WBRT which cannot be negli-
gible. Actually the time course of WBRT-induced NCF
decline can vary greatly according to the specific neuro-
behavioral domains measured. Early neurocognitive de-
cline occurs within the first one to four months after the
patient receives the course of WBRT for brain metasta-
ses [6]. The domains of radiation-related neurocognitive
decline should mainly encompass immediate and de-
layed verbal memory with or without non-verbal mem-
ory [7, 8]. According to the study reported by Sun et al.
[7], verbal memory function was most likely to deterior-
ate significantly after whole brain irradiation; however,
general nonspecific cognitive functions and quality of life
were not adversely influenced after receiving.
Over the past several decades ago, it has been estab-
lished that hippocampus plays an essential role in mem-
ory function [9]. Additionally, not little evidence
suggests that impaired hippocampal neurogenesis result-
ing from cranial irradiation [10–13] should be strongly
associated with NCF impairment [9, 14]. Moreover, a
few studies demonstrated that the isodose distribution
irradiating the hippocampus is definitely related to NCFs
after cranial irradiation in patients with primary brain
tumors [15–17] or in those with nasopharyngeal carcin-
oma [18, 19]. As a result, it has been hypothesized that
conformal hippocampal sparing during the course of
WBRT (HS-WBRT) would provide meaningful preserva-
tion in terms of cognitive function [20–22]. Additionally,
thanks to the great advancement in radiotherapy tech-
niques such as volumetric-modulated arc therapy
(VMAT) and helical tomotherapy, it is feasible to
achieve conformal avoidance of the centrally located
hippocampus while maintaining uniform dose delivery
to the remaining brain [23–25]. Our pilot study and un-
published preliminary results also have clearly suggested
that HS-WBRT should be a feasible and recommended
technique which provides satisfactory intracranial con-
trol and preserves responsible NCFs simultaneously in
patients with favorable prognosis harboring a limited
burden of brain metastases. Besides, we should pay at-
tention to the concern whether hippocampal sparing
would increase the potential risk of metastases occurring
inside or close to the hippocampus. According to the
study reported by Ghia et al. [20], a 5-mm margin
around the hippocampus for conformal avoidance dur-
ing WBRT represents an acceptable risk. Furthermore,
the sites of relapse after HS-WBRT uncommonly de-
velop perihippocampally if patients undergoing HS-
WBRT indeed harbor a limited burden of brain
metastases.
Therefore, the current study not only aims to con-
firm the impact of the delivery of HS-WBRT on the
extent of NCF changes in patients receiving hippo-
campal sparing during the WBRT course using VMAT
technique, but also to investigate especially the rela-
tionship between hippocampal dosimetry and neuro-




Patients with primary lung cancer referred for PCI or
adults with pathologically-confirmed non-hematopoietic
malignancy and brain metastasis who had fair to good
performance status represented by Karnofsky Perform-
ance Status (KPS) score 70 or Eastern Cooperative On-
cology Group (ECOG) score 2 were eligible for this
study. Additionally, the number and extent of brain
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metastatic lesions should be no more than three meta-
static foci with a limitation of greatest diameter less than
4 cm. In addition, this inclusion criterion was confirmed
in patients by performing brain magnetic resonance im-
aging (MRI) after they underwent craniotomy with
tumor removal and before the course of WBRT if poten-
tially eligible patients were surgically resected cases.
Thus, in addition to patients referred for PCI, most of
our enrolled patients should correspond with the defin-
ition of oligometastatic brain disease, implying that the
number of metastatic foci was three or less shown on
brain MRI [26, 27]. Accordingly, patients must fall into
RTOG recursive partitioning analysis (RPA) class I or II
[28, 29]. A table describing the characteristics of our pa-
tient cohort is summarized in Additional file 1: Table S1.
Of note, there are other potential patient-, disease-,
and treatment factors which also play a role in affecting
NCF change, such as the extent of brain edema caused
by the metastatic brain focus per se or surgical interven-
tion, the confounding effect of increased intracranial
pressure (IICP), nutritional condition, and electrolyte
imbalance. Nevertheless, our pre-defined strict inclusion
criteria have focused our enrolled patients on those with
satisfactory performance status and a limited number
and burden of metastatic brain foci. As a consequence,
it is indeed assumed that the impact of potential con-
founders can be kept as negligible as possible provided
that the enrolled patients really meet our eligibility cri-
teria (unpublished results).
Given the concerns of safety issue whether reducing
the dose delivered to hippocampal areas below the
therapeutic level might potentially increase the risk of
hippocampal metastasis, patients with MRI-identified
metastasis within 5 mm perihippocampally were ex-
cluded. Other exclusion criteria include clinical suspi-
cion of leptomeningeal spreading, a history of prior
radiotherapy including stereotactic radiosurgery deliv-
ered to brain/head region for any reasons, and contra-
indication for receiving contrast-enhanced MRI
examination.
The study protocol had been approved by the institu-
tional review board (IRB) at our institute (IRB 101-
4151B and 103-1090C) and written informed consent
was obtained from each enrolled and eligible patient or
the person authorized to give consent. Of note, the
current study is a principle investigator (PI)-initiated
study; neurosurgeons and radiation oncologists consti-
tute the main investigators taking responsibility for
recruiting appropriate patients for this prospective
study.
Neurocognitive assessments
No matter whether the enrolled patients are surgically
resected cases or not, Gadolinium-enhanced MRI should
be obtained within one month prior to the planned
course of HS-WBRT in order to ensure that potentially
eligible patients had no any detected brain metastasis
within a 5-mm margin around either hippocampus on
MRI. Similarly, relevant physical examination and sta-
ging oncological surveys should be performed within
30 days before the initiation of HS-WBRT course. Most
importantly, all participants must receive the baseline
neurocognitive assessment (mentioned below), which
was administered within two weeks before the start of
HS-WBRT course. Besides, the time interval between
brain MRI examination and baseline neurocognitive test-
ing is as short as possible, preferably within two weeks.
A selective neurobehavioral test battery is pre-
determined and administered in this prospective study
as shown in Table 1. The neurobehavioral measures
mainly evaluate several domains assumed to be sensitive
to the tumor involvement and the impact of cranial radi-
ation therapy; all tests were administered by a trained
clinical research associate under the supervision of a
neuropsychologist.
Since the delivery of HS-WBRT instead of conven-
tional WBRT aims to diminish the extent of neurotoxic
impact on the hippocampus, which is significantly asso-
ciated with memory functions [9, 16, 22, 30], three main
aspects of NCF including memory functions, executive
functions, and psychomotor speed are thus evaluated.
First, regarding the domain of memory, the selected sub-
tests of the Wechsler Memory Scale- 3rd edition
(WMS-III) were used to evaluate patients’ verbal and
non-verbal episodic memory. In terms of verbal mem-
ory, the Word Lists (WL) Subset was used, while the
Visual Reproduction (VR) Subtest was employed to as-
sess the capability of non-verbal memory. Second, con-
cerning the aspect of executive functions, the Modified
Card Sorting Test [31] is used to assess both conceptual
formation and mental shifting which have been docu-
mented to be the major components of executive func-
tions. Conceptual formation is represented by the score
obtained from the number of completed categories (CC)
and mental shifting is depicted by the score from the
number of preservative errors (PE). Besides, the Digit
Span Subtest (DS) subset of the Wechsler Adult
Intelligence Scale- 3rd edition (WAIS-III®) [32] was used
to examine the verbal working memory. Finally, in order
to determine the patients’ performance on the psycho-
motor speed, Psychomotor Speed Index (PSI), which is
derived from the composite score of Digit Symbol Cod-
ing Subtest (DSS) and Symbol Searching Subtest (SS) of
the WAIS-III®, was used.
Treatment planning and delivery
All enrolled patients underwent a computed tomography
(CT) simulation scan encompassing the entire head
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region with 1.25-mm slice thickness using a thermoplas-
tic mask for immobilization. Bilateral hippocampal areas
were contoured on T1-weighted sequence of axial mag-
netic resonance imaging (MRI) with gadolinium contrast
enhancement. Hippocampal contouring was created and
confirmed by a same experienced neuroradiologist.
Figure 1(a)-(c) displays that appropriate anatomical con-
touring was also modified and verified by using T1-
weighted MRI coronal and sagittal sequences. Further-
more, the hippocampal avoidance zone (HA zone) was
generated by expanding the hippocampal outlines with a
margin of 5-mm volumetrically to allow for the sharp
dose fall-off between bilateral hippocampal structures
and the planning target volume (PTV) of whole brain.
[23].
To achieve conformal hippocampal sparing during the
delivery of WBRT, the technique of volumetric modu-
lated arc therapy (VMAT) was employed with using lin-
ear accelerator. Two full arcs and two non-coplanar arcs
of VMAT were designed in VMAT treatment planning
as shown in Fig. 1(d). The prescribed dose was 25Gy in
10 fractions for prophylactic WBRT or 30 Gy delivered
in 10 to 12 fractions for therapeutic or adjuvant WBRT.
General principles for target coverage are 100 % cover-
age for tumor bed and/or gross metastatic tumor, 95 %
coverage for clinical target volume (CTV) and 90 %
Table 1 The neurocognitive test battery administered at baseline and 4 months after the course of HS-WBRT
Neurocognitive Function Test Domain
Memory
WMS-III Word Lists (immediate, delayed recall and recognition) Verbal memory
WMS-III Visual Reproduction (immediate, delayed recall and recognition) Visual memory
WAIS-III Digit Span Working memory
Processing speed
WAIS-III Digit Symbol Psychomotor speed
WAIS-III Symbol Search Tests Psychomotor speed
Executive Functions
Wisconsin Card Sorting Test Cognitive flexibility
Abbreviations: WMS wechsler memory scale, WAIS wechsler adult intelligence test
Fig. 1 An example of hippocampi contouring was demonstrated in (a) Axial, (b) Coronal and (c) Sagittal views. The bilateral hippocampal
structures were contoured in yellow color. The zone for hippocampus avoidance (HA zone) was marked in orange. d Treatment planning was
designed and arranged by four arcs in a VMAT plan, in which two full arcs and two non-coplanar partial arcs were employed
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coverage for planning target volume (PTV) with hot
spots receiving less than 115 % of the prescription dose.
Furthermore, In order to reflect the corresponding ef-
fects of different levels of biologically equivalent doses,
all the doses described as follows would be transformed
to the equivalent doses in 2-Gy fractions (EQD2) assum-
ing α/β = 2 Gy. Regarding the hippocampal dosimetry,
the percentage of a hippocampal volume receiving at
least m% of the prescribed dose was presented as Vm%;
the dose irradiating at most q% of the hippocampal vol-
ume was indicated by Dq%. For example, D40% corre-
sponds to the EQD2 irradiating 40 % of the hippocampal
volume of interest. Owning to the principle of hippo-
campus sparing which must indicate a sharp dose fall-off
within the small volume of the hippocampal structure, it
should be anticipated that the larger the q% is, the lower
the corresponding dose of Dq% is.
Generally, the hippocampus sparing in our study
would be achieved by limiting V40% less than 15 % or as
low as achievable while maintaining acceptable target
coverage. The dose volume histograms (DVH) for each
patient were generated for left hippocampus, right
hippocampus, and the composite structure of bilateral
hippocampi, individually. Before performing the analyses
addressing the correlations between dosimetric parame-
ters and NCF scores of interest, we retrieved from the
Eclipse treatment planning system quite a few dosimet-
ric variables, including the hippocampal volume of inter-
est and the various dose levels irradiating the
hippocampal structure. All physical doses were con-
verted to biologically equivalent doses in 2-Gy fractions
(EQD2) assuming an α/β ratio of 2 Gy.
Statistical analysis
The primary neurocognitive endpoint was delayed re-
call, as determined by the change/decline in either
verbal memory [WMS III – Word Lists (WL)] or
non-verbal memory [WMS III - Visual Reproduction
(VR)] from baseline pre-WBRT assessment to
4 months after the start of HS-WBRT. As a result, to
compare patients’ NCFs before and after the HS-
WBRT course, the repeated measure analysis of
variance (ANOVA) was utilized. The statistical signifi-
cance was set as p value of less than 0.05 after the
Bonferroni adjustment.
Concerning neurocognitive outcomes, each patient
served as his/her own control, therefore the change in
NCF scores for each subtest from baseline to 4-month
after the HS-WBRT course was calculated as the post-
WBRT normalized score minus the baseline normalized
one. By comparing the NCF scores between pre-RT and
post-RT regarding the HS-WBRT course, patients in this
study were dichotomized into binary groups according
to the median value of each hippocampal dosimetric
parameter. If the change in the NCF score under investi-
gation in one patient shows neurocognitive improve-
ment, this patient will be categorized as the group with
NCF preservation group; all the others will be among
the group without experiencing NCF preservation
Before performing the analyses addressing the correla-
tions between dosimetric parameters and NCF scores of
interest, the median and mean volumes for individual or
composite hippocampal structures were extracted from
Eclipse treatment planning system and subsequently
converted into EDQ2 values as stated previously. First,
according to the medians of the above various levels of
EQD2 values, within each dosimetric parameter, the
dosimetric data were categorized into a higher dose sub-
group and a lower one, using the median as the cut-off
point. Second, the changes in NCF scores between base-
line and 4-months after the HS-WBRT course were clas-
sified as a subgroup of patients experiencing
neurocognitive preservation and the other patient sub-
group without achieving NCF preservation. Neurocogni-
tive preservation was defined that the change in the
specific NCF score of interest was more than zero. Fi-
nally, the association between each dosimetric parameter
of interest and various NCF scores were extensively in-
vestigated by using the chi-square test. Binary logistic re-
gression was also employed to investigate the
independent effects of hippocampal dosimetric parame-
ters on NCF change (decline vs. no decline); adjusted
ORs were computed to stand for the independent effects
of the dosimetric parameters of interest after controlling
for the patient’s age at study enrollment and whether
craniotomy with tumor removal was performed or not
before undergoing the course of HS-WBRT.
Results
Neurocognitive outcomes directly related to
hippocampus-dependent memory functions
All recruited patients in this prospective study should
receive baseline NCF assessment before undergoing the
subsequent HS-WBRT course. Overall compliance with
NCF testing was 68 % at months after the initiation of
HS-WBRT course. The majority of failure to achieve
compliance should be ascribed to patient-related factors
such as an unsatisfactory performance status impeding
the administration of neurocognitive assessment. Conse-
quently, there were totally 24 patients whose post-
treatment follow-up NCF assessment was available. With
regard to neurocognitive outcomes in our study, gener-
ally NCF scores were relatively stable before and after
HS-WBRT, in terms of immediate and delayed verbal/
non-verbal memory. Remarkably, neurocognitive
stabilization was the mainly observed finding rather than
NCF decline. For instance, With regard to the verbal
memory reflecting the episodic memory function of left
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hippocampus, no significant difference in the scaled scores
of the short-term or long-term memory on the Word List
learning (WLL) was observed between before and after the
course of HS-WBRT (F =1.402, p =0.248, for short-term
memory; F =0.006, p =0.969, for long-term memory). Im-
portantly, the change in verbal memory indicated by WLL
tends to stabilize and even improve rather than decline. As
well, with respect to the non-verbal memory indicating the
episodic memory function of right hippocampus, the
change in any scaled scores on Visual Reproduction (VR)
between pre- and post-WBRT course also tended to be-
come stabilized with somewhat improvement (F =1.125, p
=0.3, for short-term memory; F =0.397, p =0.535, for long-
term memory; F =10.18, p =0.004, for recognition).
Performance of VMAT plan and DVH results of the
hippocampal structure
Figure 2 shows that hippocampus sparing was generally
accomplished with satisfactory target coverage and
conformity in our study. Based on the DVH results in this
study, the V90% of PTV ranges from 96.51 to 99.88 %
(98.08 ± 0.907 %) and the dose percentages corresponding
to the 1c.c. hot spot areas were between 108.64 % and
114.38 % (112.036 ± 1.615).
In terms of hippocampus sparing via VMAT achieved in
our study, the volume percentage of V40% ranges from
0.24 to 71.44 % (15.42 ± 17.34 %) for left hippocampus
and between 0.215 and 63.05 % (15.3 ± 17.528 %) for right
hippocampus (Unpublished results). Axial views illustrat-
ing different sections of conformal hippocampus avoid-
ance were shown in Fig 3. It apparently demonstrates that
normal tissue sparing via our VMAT planning is achieved
not only for the hippocampal structure but also for the
eyes, while target coverage and conformity are maintained
simultaneously.
The descriptive data of hippocampal dosimetric parame-
ters converted to the corresponding EQD2 values are listed
in Table 2. The volumes of each individual hippocampus
Fig. 2 An example of 90 % isodose distribution in the display modes of color wash and dose volume histogram (DVH). a Axial, b Coronal, c
agittal views and (d) The displayed DVH is in accordance with the prescription of 3000 cGy in physical dose. The yellow curve outlines where the
bilateral hippocampal structures are, red for PTV, blue for CTV, and orange for the region of gross tumor or tumor bed
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range from 2.20 c.c. to 2.79 c.c., with a mean volume of
2.41 c.c. for left hippocampus and 2.71 c.c. for right hippo-
campus. According to the EQD2 dose values of D20%, D40%,
D50% and D80% irradiating the hippocampal structure of
interest, it is noted that both left and right hippocampal
structures can be spared approximately the similar dose
levels in this study, generally below the EQD2 value of
8.5 Gy.As for the median EQD2 values of maximal and
minimal dose levels irradiating the hippocampal structure
of interest, they are 12.6 Gy and 5.8 Gy for left hippocam-
pus, and 12.4 Gy and 5.7 Gy for right hippocampus
respectively.
Fig. 3 The isodose region without added color display represents the site of hippocampal sparing. The 40 % isodose displayed in color wash
indicates where our VMAT treatment plan has attempted to achieve so-called hippocampal sparing
Table 2 A summary of hippocampal dosimetric parameters used in this study
Bilateral hippocampi Left hippocampus Right hippocampus
Mean (95 % CI) Median Mean (95 % CI) Median Mean (95 % CI) Median
Volume (c.c.) 4.99 (4.59–5.40) 5.18 2.41 (2.20–2.62) 2.41 2.58 (2.37–2.79) 2.71
Maximum EQD2 (Gy) 13.51 (11.85–15.17) 12.64 13.20 (11.50–14.9) 12.41 12.93 (11.64–14.22) 12.64
D20% EQD2 (Gy) 8.30 (7.81–8.78) 8.26 8.34 (7.86–8.82) 8.22 8.27 (7.78–8.76) 8.28
D40% EQD2 (Gy) 7.65 (7.19–8.11) 7.68 7.67 (7.22–8.12) 7.70 7.63 (7.16–8.10) 7.70
D50% EQD2 (Gy) 7.40 (6.96–7.85) 7.45 7.41 (6.97–7.85) 7.48 7.37 (6.92–7.82) 7.47
D80% EQD2 (Gy) 6.70 (6.32–7.07) 6.80 6.72 (6.35–7.09) 6.73 6.69 (6.30–7.07) 6.84
Minimum EQD2 (Gy) 5.78 (5.51–6.04) 5.82 5.61 (5.04–6.18) 5.73 5.86 (5.58–6.14) 5.90
Abbreviations: D10% biologically equivalent dose in 2-Gy fractions (EQD2) assuming α/β = 2Gy to 10 % of the hippocampus volume of interest (left, right, or
bilateral); therefore, Dm% is defined as the EQD2 to m% of the hippocampal volume of interest; D100% = the EQD2 to 100 % of the structure volume, corresponding
to the minimal dose received by the hippocampus of interest in our study; Maximum the maximal EQD2 irradiating the hippocampus volume of interest
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Correlation of Hippocampal dosimetry with
neurocognitive functions
First of all, based on the medians of different levels of
EQD2 values of each dosimetric parameter, the dosimetric
data were categorized into two subgroups. Second, as
shown in Tables 3 and 4, the changes in neurocognitive
scores between baseline and 4-month after the HS-WBRT
course were classified as two subgroups according to
whether neurocognitive preservation was achieved or not.
Finally, the correlations of each dosimetric parameter of
interest with various NCF scores were extensively examined
and reported.
To summarize the statistically significant findings in our
initial analyses by using chi-square test, it was noted that
Table 3 Correlation of hippocampal dosimetry with the status of NCF change in verbal memory after HS-WBRT
Dosimetric parameters Dosimetric cut-off points NCF Preservation N (%) No preservation p value
Bilateral hippocampi as a composite structure
Maximum ≤12.6 Gy 10(83.3 %) 2(16.7 %) 0.004*
>12.6 Gy 3(25.0 %) 9(75.0 %)
D10% ≤8.81 Gy 9(75.0 %) 3(25.0 %) 0.041*
>8.81 Gy 4(33.3 %) 8(66.7 %)
D20% ≤8.26 Gy 8(66.7 %) 4(33.3 %) 0.219
>8.26 Gy 5(41.7 %) 7(58.3 %)
D30% ≤7.95 Gy 8(66.7 %) 4(33.3 %) 0.219
>7.95 Gy 5(41.7 %) 7(58.3 %)
D40% ≤7.68 Gy 8(66.7 %) 4(33.3 %) 0.219
>7.68 Gy 5(41.7 %) 7(58.3 %)
D50% ≤7.45 Gy 9(75.0 %) 3(25.0 %) 0.041*
>7.45 Gy 4(33.3 %) 8(66.7 %)
D80% ≤6.80 Gy 9(75.0 %) 3(25.0 %) 0.041*
>6.80 Gy 4(33.3 %) 8(66.7 %)
D100% ≤5.83 Gy 9(75.0 %) 3(25.0 %) 0.041*
>5.83 Gy 4(33.3 %) 8(66.7 %)
Left hippocampus
Maximum ≤12.41 Gy 10(83.3 %) 2(16.7 %) 0.004*
>12.41 Gy 3(25.0 %) 9(75.0 %)
D10% ≤8.75 Gy 9(75.0 %) 3(25.0 %) 0.041*
>8.75 Gy 4(33.3 %) 8(66.7 %)
D20% ≤8.22 Gy 8(66.7 %) 4(33.3 %) 0.219
>8.22 Gy 5(41.7 %) 7(58.3 %)
D30% ≤7.94 Gy 8(66.7 %) 4(33.3 %) 0.219
>7.94 Gy 5(41.7 %) 7(58.3 %)
D40% ≤7.70 Gy 9(75.0 %) 3(25.0 %) 0.041*
>7.70 Gy 4(33.3 %) 8(66.7 %)
D50% ≤7.48 Gy 9(75.0 %) 3(25.0 %) 0.041*
>7.48 Gy 4(33.3 %) 8(66.7 %)
D80% ≤6.73 Gy 9(75.0 %) 3(25.0 %) 0.041*
>6.73 Gy 4(33.3 %) 8(66.7 %)
D100% ≤5.73 Gy 8(66.7 %) 4(33.3 %) 0.219
>5.73 Gy 5(41.7 %) 7(58.3 %)
The status of neurocognitive change shown here is according to patients’ performance on the immediate recall of Wechsler Memory Scale-III Word Lists. The
association between hippocampal dosimetry and the status of NCF change (preservation or not) in verbal memory 4 months after the HS-WBRT course was
evaluated by using chi-square test for the 24 patients in whom post-treatment NCF assessment was available
The N (%) is listed to stand for the number of patients and its corresponding percentage
* indicates that statistical significance is noted
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the EQD2 of maximal dose, D10%, D50%, D80%, and minimal
dose delivered to bilateral hippocampi with <12.60 Gy,
<8.81 Gy, <7.45 Gy, <6.80 Gy and <5.83 Gy respectively
were significantly associated with functional preservation
in Wechsler Memory Scale-III Word List (WMS-WL) im-
mediate recall (p-values =0.004, 0.041, 0.041, 0.041 and
0.041, respectively) as listed in Table 3. Similarly, the
above correlations also existed between hippocampal
dosimetry specific to left hippocampus and functional
preservation in immediate recall of WMS-WL. By con-
trast, there were no any significant associations observed
between the dosimetric parameters tailored to right
hippocampus and verbal functional preservation indicated
by WMS-WL, as we had anticipated.
Besides, it was not found that there were any statistically
significant dosimetric correlations with neurocognitive
Table 4 Association between hippocampal dosimetry and the status of NCF change in Wisconsin Card Sorting Test
Dosimetry Dosimetric cut-off points NCF Preservation N (%) No preservation p value
Bilateral hippocampi as a composite structure
Maximum ≤12.6 Gy 9(75.0 %) 3(25.0 %) 0.098
>12.6 Gy 5(41.7 %) 7(58.3 %)
D10% ≤8.81 Gy 7(58.3 %) 5(41.7 %) 1
>8.81 Gy 7(58.3 %) 5(41.7 %)
D20% ≤8.26 Gy 7(58.3 %) 5(41.7 %) 1
>8.26 Gy 7(58.3 %) 5(41.7 %)
D30% ≤7.95 Gy 6(50.0 %) 6(50.0 %) 0.408
>7.95 Gy 8(66.7 %) 4(33.3 %)
D40% ≤7.68 Gy 6(50.0)% 6(50.0 %) 0.408
>7.68 Gy 8(66.7 %) 4(33.3 %)
D50% ≤7.45 Gy 7(58.3 %) 5(41.7 %) 1
>7.45 Gy 7(58.3 %) 5(41.7 %)
D80% ≤6.80 Gy 7(58.3 %) 5(41.7 %) 1
>6.80 Gy 7(58.3 %) 5(41.7 %)
D100% ≤5.83 Gy 7(58.3 %) 5(41.7 %) 1
>5.83 Gy 7(58.3 %) 5(41.7 %)
Left hippocampus
Maximum ≤12.41 Gy 10(83.3 %) 2(16.7 %) 0.013*
>12.41Gy 4(33.3 %) 8(66.7 %)
D10% ≤8.75Gy 7(58.3 %) 5(41.7 %) 1
>8.75 Gy 7(58.3 %) 5(41.7 %)
D20% ≤8.22 Gy 7(58.3 %) 5(41.7 %) 1
>8.22 Gy 7(58.3 %) 5(41.7 %)
D30% ≤7.94 Gy 7(58.3 %) 5(41.7 %) 1
>7.94 Gy 7(58.3 %) 5(41.7 %)
D40% ≤7.70 Gy 7(58.3 %) 5(41.7 %) 1
>7.70 Gy 7(58.3 %) 5(41.7 %)
D50% ≤7.48 Gy 7(58.3 %) 5(41.7 %) 1
>7.48 Gy 7(58.3 %) 5(41.7 %)
D80% ≤6.73 Gy 7(58.3 %) 5(41.7 %) 1
>6.73 Gy 7(58.3 %) 5(41.7 %)
D100% ≤5.73 Gy 7(58.3 %) 5(41.7 %) 1
>5.73 Gy 7(58.3 %) 5(41.7 %)
The status of neurocognitive change shown here is tailored to patients’ performance on Wisconsin Card Sorting Test – Perseverative Errors 4 months after the HS-
WBRT course in 24 patients
The N (%) is listed to represent the number of patients and its corresponding percentage
* indicates that statistical significance is noted
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preservation of visual reproduction governed generally by
right hippocampus (Data not shown). Moreover, as shown
in Table 4, the EQD2 of maximal dose irradiating left
hippocampus with <12.41 Gy was significantly associ-
ated with functional preservation in preservative er-
rors of Wisconsin Card Sorting Test (p-value =0.013).
As illustrated in Fig 4, it provides us a direct
visualization of how hippocampal dosimetry might correl-
ate with neurocognitive change after the course of HS-
WBRT with several scatter plots. Theoretically thinking,
the higher EQD2 the hippocampus receives, the less likely
the responsible neurocognitive function is to be preserved.
Herein, only the scatter plots concerning the hippocampal
dosimetry delivered to left hippocampus are selectively
displayed. It is shown that among the dose levels of max-
imal dose, D10% D40%, D50%, and D80% delivered to left
hippocampus, the lower the corresponding EQD2 is, the
more likely left hippocampus-dependent verbal memory
would be preserved according to the specific test of Word
List Learning-Immediate Recall (WLL-IR).
Based on the binary logistic regression analyses per-
formed to examine the potential impacts of hippocam-
pal dosimetric parameters on NCF change after the
course of HS-WBRT, it seemed that dosimetric parame-
ters specific to left sided hippocampus exerted an influ-
ence on immediate recall of verbal memory rather than
its long-term delayed recall and recognition counter-
parts. As demonstrated in Table 5, the minimal dose ir-
radiating left hippocampus indeed imposes an
independent effect on the specific neurocognitive func-
tion, immediate recall of verbal memory (WLL-IR).
Similarly, the mean dose delivered to left hippocampus
also confers a statistically significant influence on im-
mediate recall of verbal function. Quantitatively, as the
above mean dose (converted to EQD2) increases by one
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Fig. 4 Scatter plots displaying the association between hippocampal dosimetry and neurocognitive functions. Each colored dot represents
the change in the NCF scores obtained between before and after the HS-WBRT course for each individual patient. Horizontal axis indicates
the hippocampal dosimetry irradiating left hippocampus in a unit of Gy converted to the equivalent dose in 2-Gy fractions (EQD2). Vertical axis
represents the extent of the NCF change; negative values indicate that there is a specific neurocognitive decline in immediate recall of
verbal memory (WLL-IR) after the course of HS-WBRT. Of note, a dotted vertical line in each panel stands for the median dose irradiating
left hippocampus in a unit of Gy (EQD2). Moreover, the shadowed areas in each panel support the theoretical hypothesis that the higher
EQD2 the hippocampus receives, the less likely the corresponding NCF is to be spared
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approximately in the risk for patients in our study to ex-
perience a neurocognitive decline in immediate recall of
verbal memory (WLL-IR) after the HS-WBRT course
(adjusted odds ratio, 4.08; p-value, 0.042; 95 % confi-
dence interval, 1.055 – 15.780). Nevertheless, as for the
dosimetric parameters tailored to right side hippocam-
pus, it seemed that there were no observed independent
effects of right hippocampus-specific dosimetric param-
eters on verbal or non-verbal memory (Data not
presented).
Discussion
Significance of this prospective study
Since only one intracranial failure in the current study
might be associated with the dose-reducing region indi-
cating the zone of hippocampal avoidance (unpublished
results), we believe that reducing the dose irradiating the
hippocampal areas when treating patients with WBRT
might not compromise intracranial tumor control. Fur-
thermore, several related studies have consistently sup-
ported selectively reducing the dose delivered to the
Table 5 Binary regression analyses addressing the impact of hippocampal dosimetric parameters on patients’ verbal memory
NCF tests Dosimetric parameters Crude OR (p-value) Adjusted OR Statistical significance 95 % CI
WLL-IR
R-hippo mean 2.232 (p = 0.108) 2.901 0.077 0.893–9.424
R-hippo max 1.026 (p = 0.856) 1.040 0.802 0.763–1.419
R-hippo min 4.380 (p = 0.077) 5.818 0.061 0.920–36.805
L-hippo mean 2.870 (p = 0.060) 4.080 0.0420* 1.055–15.780
L-hippo max 1.003 (p = 0.975) 1.012 0.920 0.802–1.276
L-hippo min 7.903 (p = 0.037*) 14.345 0.040* 1.126–182.689
B-hippo mean 2.569 (p = 0.076) 3.510 0.052 0.989–12.460
B-hippo max 1.004 (p = 0.974) 1.011 0.930 0.797–1.282
B-hippo min 5.333 (p = 0.070) 8.147 0.060 0.917–72.401
WLL-LTDR
R-hippo mean 1.114 (p = 0.805) 1.169 0.769 0.413–3.313
R-hippo max 0.894 (p = 0.551) 0.883 0.652 0.513–1.519
R-hippo min 1.203 (p = 0.784) 1.339 0.716 0.277–6.481
L-hippo mean 1.218 (p = 0.665) 1.366 0.581 0.452–4.129
L-hippo max 0.926 (p = 0.596) 0.973 0.864 0.711–1.332
L-hippo min 1.784 (p = 0.352) 2.249 0.322 0.453–11.178
B-hippo mean 1.176 (p = 0.718) 1.291 0.643 0.438–3.809
B-hippo max 0.918 (p = 0.574) 0.938 0.738 0.644–1.366
B-hippo min 1.349 (p = 0.672) 1.612 0.584 0.292–8.897
WLL-R
R-hippo mean 0.994 (p = 0.990) 1.262 0.699 0.389–4.093
R-hippo max 1.321 (p = 0.183) 3.091 0.147 0.671–14.232
R-hippo min 1.481 (p = 0.616) 1.966 0.430 0.367–10.528
L-hippo mean 1.177 (p = 0.757) 1.573 0.460 0.473–5.234
L-hippo max 1.370 (p = 0.209) 2.290 0.084 0.894–5.868
L-hippo min 1.669 (p = 0.465) 2.199 0.357 0.412–11.746
B-hippo mean 1.089 (p = 0.870) 1.424 0.563 0.430–4.718
B-hippo max 1.309 (p = 0.214) 2.308 0.114 0.817–6.521
B-hippo min 1.632 (p = 0.551) 2.273 0.363 0.388–13.305
Abbreviations: WLL word list learning of Wechsler memory scale-III, IR immediate recall, LTDR long term delayed recall, R recognition, R-hippo right hippocampus,
L-hippo left hippocampus, B-hippo bilateral hippocampi as a composite structure, OR odds ratio, CI confidence Interval
The NCF test results shown here are derived from of Wechsler Memory Scale-III Word Lists
Adjusted OR represents the independent effect of the dosimetric parameter of interest after controlling for the patient’s age at study recruitment and whether
craniotomy with tumor removal was performed or not before the referral to our Department of Radiation Oncology
The status of neurocognitive change shown here is according to patients’ performance on verbal memory indicated by Wechsler Memory Scale-III Word Lists
* indicates that statistical significance is noted
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hippocampus when treating oligometastatic patients
with WBRT [26, 27, 33, 34].
Although our results have clearly shown that specific
NCFs (i.e., verbal and non-verbal learning memory, ex-
ecutive functions, and psychomotor speed) do not sig-
nificantly change or decline in patients who have
undergone hippocampal sparing during the WBRT
course, our findings might just be applied to the time
span of 4 months after HS-WBRT and a decline after
this time point cannot be utterly excluded. Nevertheless,
the changes in most of the specific NCFs assessed in our
study tend to stabilize and even improve rather decline
as what have usually been anticipated.
Meaningful implications arising from hippocampal
dosimetry analyses
In the study reported by Gondi et al. [16], it was docu-
mented that the biologically equivalent dose in 2-Gy
fractions (EQD2) to 40 % of the composite structure of
bilateral hippocampi greater than 7.3 Gy was signifi-
cantly associated with neurocognitive impairment re-
garding the delayed recall of WMS-WL. Looking back to
our current study which also adopted the same verbal
learning test (WMS-WL), it is indeed observed that the
dosimetric parameters concerning particularly left
hippocampus imposes an independent influence on the
immediate recall of verbal memory rather than its de-
layed recall or recognition counterparts. Nevertheless,
our results do support the hypothesis that verbal mem-
ory is likely to be impaired by local irradiation in a
dose–response relationship.
By contrast, we failed to find any correlations existing
between hippocampal dosimetry and the non-verbal
memory function indicated by the NCF test of visual
reproduction (WMS-VR). Such negative findings are
quite consistent with those reported by Gondi et al. [16];
and therefore some plausibility might be proposed to po-
tentially explain the above negative results. First, non-
verbal memory learning is less likely to be hampered
after exposure to irradiation or more likely to be com-
pensated for by other related neurocognitive functions
and circuits. Second, it is possible that the administered
NCF test (WMS-VR) is too insensitive to detect the sub-
tle non-verbal memory decline after the course of HS-
WBRT, during which only a median EQD2 of 7.68 Gy
converted to a biologically equivalent dose in 2-Gy frac-
tions is delivered to 40 % of the composite hippocampal
structure. Indeed, the past evidence has proved that the
spatial learning ability is significantly associated with the
hippocampal functions [35]. In addition, participants’
performance on WMS-VR mainly requires specific re-
calls from the given geometric shapes, which do not ne-
cessarily involve the information of spatial relations.
Therefore, the negative findings concerning the impact
of dosimetric parameters on the scores of WMS-VR
might be reasonable.
Strengths and potential limitations of the present study
To the best of our knowledge, there has been little
evidence investigating neurocognitive outcomes for
non-primary brain tumor patients, let alone cancer
patients with brain metastasis in Taiwanese popula-
tion. Therefore, this prospective clinical study with
neurocognitive outcome research might be a pioneer-
ing study focusing on neurocognitive outcomes in the
field of neuro-oncology in an eastern Asian country.
Moreover, all contouring tailored to the imaging anat-
omy of the hippocampus was consistently delineated
and verified by the same neuroimaging radiologist in-
stead of neurosurgeons or radiation oncologists only.
Similarly, all neurocognitive assessments were admin-
istered under the supervision of an experienced
neuropsychologist, who had selected a neurobehav-
ioral test battery specifically for the current study. By
virtue of this prospective study carried out in Taiwan,
we can not only acquire both neurocognitive and
neuro-oncological results, but also have the great op-
portunity to correlate hippocampal dose-volume histo-
gram (DVH) data with neurocognitive functional
outcomes. Definitely these objective results will guide
us helpfully when formulating and designing the fu-
ture study protocols.
Even though the current study has apparently
shown that neurocognitive functions tended to
stabilize instead of decline after HS-WBRT, we should
always be aware that patients experiencing perhaps
the worst neurocognitive status due to any reasons
after HS-WBRT might fail to receive the neurocogni-
tive follow-up assessment because of non-compliance.
As a consequence, we have to interpret our neurocog-
nitive data more cautiously in order not to be masked
by such a potential bias. Besides, even though this
prospective study might be limited by the fact that
there is no real control group for which conventional
WBRT without hippocampal sparing is delivered, ac-
tually each patient indeed serves as his/her own con-
trol, because the difference in scores obtained at
baseline and at pre-specified post-treatment intervals
will be measured and calculated. The patient popula-
tion in this prospective study actually reflects the real
world patient management in our country, where
WBRT combined with/without surgical removal in-
stead of upfront radiosurgery can generally be reim-
bursed by national insurance when managing cancer
patients with newly-diagnosed oligometastatic brain
disease or at a higher risk of brain metastasis [36].
Therefore, we enroll two main patient subgroups; one
subgroup stands for patients referred for PCI and the
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other represents those with a limited burden of brain
metastases (unpublished results).
Neurocognitive status/change before and after HS-WBRT
Multi-domains of NCF were examined in this study, and
our results consequently showed no significant differ-
ences or declines in verbal or non-verbal memory, ex-
ecutive functions and psychomotor speed between
baseline and 4-months after the start of HS-WBRT
course; it is also found that the change in multi-domains
of NCF generally tend to become stabilized with some-
what improvement. As a matter of fact, our findings
support that the conformal sparing of hippocampal areas
during the delivery of WBRT might preserve patients’
NCF mostly or alleviate the extent of NCF changes at
least [26, 37]. Indeed, it has been documented that
WBRT is associated with late neurotoxicity resulting
from brain irradiation and will induce multi-faceted dif-
ficulties in patients including memory, attention and
motor control [8, 38]; therefore, HS-WBRT was devel-
oped to preserve cortical NCFS in patients receiving cra-
nial RT [20, 26, 39]. Although quite a few researches
[33, 40, 41] have conceptually hypothesized that HS-
WBRT might mitigate the cognitive decline after brain
RT, studies concerning the dynamic changes of NCFs
before and after HS-WBRT are still limited and prelim-
inary. For example, Gondi et al. have conducted a phase
II clinical trial, RTOG 0933, to investigate the effects of
HS-WBRT on patients with brain metastases and they
evaluated memory performances by using the Hopkins
Verbal Learning Test (HVLT) at 4 months after initiat-
ing brain RT [22]. Our prospective study further pro-
vides convincing and promising evidence that specific
NCFs in patients with oligometastatic brain disease are
quite stable between the baseline assessment and those
evaluated at 4 months after HS-WBRT.
Future directions
First of all, the dosimetric parameters utilized in the
current study are mainly biologically equivalent doses in
2-Gy fractions (EQD2) assuming an assuming an α/β
value of 2 Gy. In fact, the concept of equivalent uniform
dose (EUD) has been introduced in recent years [42, 43]
in order to determine the radiation exposure of the hip-
pocampal structure more accurately. In the future, it de-
serves investigating the correlations of EUD of the
hippocampus in patients receiving cranial irradiation
with relevant neurocognitive changes after HS-WBRT.
In addition, given the ability of modern VMAT tech-
niques to spare the hippocampal structures in excess of
the dosimetric threshold during the 30-Gy WBRT
course, we are going to explore the dosimetric findings
in ongoing and future prospective studies of hippocam-
pal sparing during cranial irradiation.
Second, whether the current study can be expended to
a larger-scale prospective study with introducing an ap-
propriate control group deserves detailed discussion and
debates. Conceptually, patients fitting the same eligibility
and randomized to receive conventional WBRT without
hippocampal sparing should be the ideal control patient
population. However, ethical considerations cannot be
avoided at all provided that HS-WBRT could achieve
similar oncological outcomes, more favorable neurocog-
nitive outcomes without violating the safety profile, as
compared with conventional WBRT [22].
Conclusions
Neurocognitive assessments provide further help for
neuro-oncologists and relevant health professionals
when managing cancer patients harboring brain metas-
tases. Additionally, both intracranial control and satisfac-
tory functional preservation by reducing the dose
irradiating the hippocampus during the WBRT course
have been achieved in the current study. The correlation
between hippocampal dosimetry and neurocognitive out-
comes would definitely guide us when formulating and
designing the future study protocols. Providing that
modern VMAT techniques can reduce the dose irradiat-
ing the hippocampus below dosimetric threshold, pa-
tients should be recruited in prospective trials of
hippocampal sparing during cranial irradiation in order
to accomplish neurocognitive preservation while main-
taining intracranial disease control.
Ethics approval
The study protocol had been approved by the institu-
tional review board (IRB) at Chang Gung Medical Foun-
dation (IRB 101-4151B and 103-1090C).
Consent for publication
Not applicable because this manuscript does not contain
any data about individual persons.
Additional file
Additional file 1: A summary of patient demographics, tumor and
disease characteristics. (PDF 86 kb)
Abbreviations
NCF: Neurocognitive Function; SCLC: small cell lung cancer;
VMAT: Volumetric Modulated Arc Therapy; WBRT: Whole Brain Radiotherapy;
HS-WBRT: Hippocampus Sparing during Whole Brain Radiotherapy;
HA: Hippocampal avoidance; DVH: Dose Volume Histogram; RPA: Recursive
partitioning analysis; PCI: prophylactic cranial irradiation; EQD2: Equivalent
Biologically equivalent doses in 2-Gy fractions; WLL: Word List Learning;
VR: Visual Reproduction; MCST: Modified Card Sorting Test; WMS: Wechsler
Memory Scale; WAIS: Wechsler Adult Intelligence Test; PSI: Psychomotor
Speed Index.
Competing interests
The authors declare that they have no competing interests.
Tsai et al. Radiation Oncology  (2015) 10:253 Page 13 of 15
Authors’ contributions
SL contributed to the study design and to the sample collection. YW,
PP, CT and YS performed the chart reviews for clinical data, follow-up
and data collection and established the clinical database. PT, TH and SL
did the statistical analysis and had access to the raw data. CY and CC
provided the infrastructural support for this study. TW conducted the
treatment planning design. The manuscript was drafted by PT, edited by
SL and CY, and submitted for comments to all the authors. All authors
approved the final version of the manuscript.
Acknowledgments
This study was supported by research grant (CMRPG3D1401) from Chang
Gung Medical Foundation, Taiwan. Trial registration: ClinicalTrial.gov
(NCT02448992).
Author details
1Department of Radiation Oncology, Chang Gung Memorial Hospital and
Chang Gung University, #15, Wenhua 1st Rd., Kwei-Shan Hsiang, Taoyuan,
Taiwan. 2Department of Medical Imaging and Radiological Sciences, College
of Medicine, Chang Gung University, Taoyuan, Taiwan. 3Department of
Occupational Therapy, Division of Clinical Psychology, Master of Behavioral
Sciences, College of Medicine, Chang Gung University, No. 259, Wen-Hwa 1st
Road, Kwei-Shan Tao-Yuan 333, Taiwan. 4Department of Neurosurgery,
Chang Gung Memorial Hospital and Chang Gung University, #5, Fu-Shin
Street, Kwei-Shan Hsiang, Taoyuan, Taiwan. 5Department of Medical Imaging
and Intervention, Chang Gung Memorial Hospital and Chang Gung
University, #5, Fu-Shin Street, Kwei-Shan Hsiang, Taoyuan, Taiwan. 6Graduate
Institute of Epidemiology and Preventive Medicine, College of Public Health,
National Taiwan University, Taipei, Taiwan.
Received: 15 October 2015 Accepted: 7 December 2015
References
1. Norden AD, Wen PY, Kesari S. Brain metastases. Curr Opin Neurol. 2005;
18(6):654–61.
2. Koay E, Sulman EP. Management of brain metastasis: past lessons, modern
management, and future considerations. Curr Oncol Rep. 2012;14(1):70–8.
doi:10.1007/s11912-011-0205-9.
3. Maclean J, Fersht N, Singhera M, Mulholland P, McKee O, Kitchen N, et
al. Multi-disciplinary management for patients with oligometastases to
the brain: results of a 5 year cohort study. Radiat Oncol. 2013;8:156. doi:
10.1186/1748-717X-8-156.
4. Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, et al.
Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J
Med. 2007;357(7):664–72. doi:10.1056/NEJMoa071780.
5. Aoyama H, Tago M, Kato N, Toyoda T, Kenjyo M, Hirota S, et al.
Neurocognitive function of patients with brain metastasis who received
either whole brain radiotherapy plus stereotactic radiosurgery or
radiosurgery alone. Int J Radiat Oncol Biol Phys. 2007;68(5):1388–95.
doi:10.1016/j.ijrobp.2007.03.048.
6. Kocher M, Soffietti R, Abacioglu U, Villa S, Fauchon F, Baumert BG, et al.
Adjuvant whole-brain radiotherapy versus observation after radiosurgery
or surgical resection of one to three cerebral metastases: results of the
EORTC 22952–26001 study. J Clin Oncol. 2011;29(2):134–41.
doi:10.1200/JCO.2010.30.1655.
7. Sun A, Bae K, Gore EM, Movsas B, Wong SJ, Meyers CA, et al. Phase III trial of
prophylactic cranial irradiation compared with observation in patients with
locally advanced non-small-cell lung cancer: neurocognitive and quality-of-
life analysis. J Clin Oncol. 2011;29(3):279–86. doi:10.1200/JCO.2010.29.6053.
8. Welzel G, Fleckenstein K, Schaefer J, Hermann B, Kraus-Tiefenbacher U,
Mai SK, et al. Memory function before and after whole brain
radiotherapy in patients with and without brain metastases. Int J Radiat
Oncol Biol Phys. 2008;72(5):1311–8. doi:10.1016/j.ijrobp.2008.03.009.
9. Scoville WB, Milner B. Loss of recent memory after bilateral hippocampal
lesions. 1957. J Neuropsychiatry Clin Neurosci. 2000;12(1):103–13.
10. Hellstrom NA, Bjork-Eriksson T, Blomgren K, Kuhn HG. Differential recovery
of neural stem cells in the subventricular zone and dentate gyrus after
ionizing radiation. Stem Cells. 2009;27(3):634–41. doi:10.1634/stemcells.2008-
0732.
11. Mizumatsu S, Monje ML, Morhardt DR, Rola R, Palmer TD, Fike JR. Extreme
sensitivity of adult neurogenesis to low doses of X-irradiation. Cancer Res.
2003;63(14):4021–7.
12. Raber J, Rola R, LeFevour A, Morhardt D, Curley J, Mizumatsu S, et al.
Radiation-induced cognitive impairments are associated with changes in
indicators of hippocampal neurogenesis. Radiat Res. 2004;162(1):39–47.
13. Rola R, Raber J, Rizk A, Otsuka S, VandenBerg SR, Morhardt DR, et al.
Radiation-induced impairment of hippocampal neurogenesis is associated
with cognitive deficits in young mice. Exp Neurol. 2004;188(2):316–30. doi:
10.1016/j.expneurol.2004.05.005.
14. Lam LC, Leung SF, Chan YL. Progress of memory function after radiation
therapy in patients with nasopharyngeal carcinoma. J Neuropsychiatry Clin
Neurosci. 2003;15(1):90–7.
15. Ali AN, Ogunleye T, Hardy CW, Shu HK, Curran WJ, Crocker IR. Improved
hippocampal dose with reduced margin radiotherapy for glioblastoma
multiforme. Radiat Oncol. 2014;9:20. doi:10.1186/1748-717X-9-20.
16. Gondi V, Hermann BP, Mehta MP, Tome WA. Hippocampal dosimetry
predicts neurocognitive function impairment after fractionated stereotactic
radiotherapy for benign or low-grade adult brain tumors. Int J Radiat Oncol
Biol Phys. 2012;83(4):e487–93. doi:10.1016/j.ijrobp.2011.10.021.
17. Marsh JC, Ziel GE, Diaz AZ, Wendt JA, Gobole R, Turian JV. Integral dose
delivered to normal brain with conventional intensity-modulated
radiotherapy (IMRT) and helical tomotherapy IMRT during partial brain
radiotherapy for high-grade gliomas with and without selective sparing of
the hippocampus, limbic circuit and neural stem cell compartment. J Med
Imaging Radiat Oncol. 2013;57(3):378–83. doi:10.1111/1754-9485.12048.
18. Han G, Liu D, Gan H, Denniston KA, Li S, Tan W, et al. Evaluation of the
dosimetric feasibility of hippocampal sparing intensity-modulated
radiotherapy in patients with locally advanced nasopharyngeal carcinoma.
PLoS One. 2014;9(2), e90007. doi:10.1371/journal.pone.0090007.
19. Khodayari B, Michaud AL, Stanic S, Wooten OH, Dublin A, Purdy JA, et al.
Evaluation of hippocampus dose for patients undergoing intensity-
modulated radiotherapy for nasopharyngeal carcinoma. Br J Radiol. 2014;
87(1037):20130474. doi:10.1259/bjr.20130474.
20. Ghia A, Tome WA, Thomas S, Cannon G, Khuntia D, Kuo JS, et al.
Distribution of brain metastases in relation to the hippocampus:
implications for neurocognitive functional preservation. Int J Radiat Oncol
Biol Phys. 2007;68(4):971–7. doi:10.1016/j.ijrobp.2007.02.016.
21. Truc G, Martin E, Mirjolet C, Chamois J, Petitfils A, Crehange G. The role of
whole brain radiotherapy with hippocampal-sparing. Cancer Radiother.
2013;17(5–6):419–23. doi:10.1016/j.canrad.2013.06.042.
22. Gondi V, Pugh SL, Tome WA, Caine C, Corn B, Kanner A, et al. Preservation
of memory with conformal avoidance of the hippocampal neural stem-cell
compartment during whole-brain radiotherapy for brain metastases (RTOG
0933): a phase II multi-institutional trial. J Clin Oncol. 2014;32(34):3810–6.
doi:10.1200/JCO.2014.57.2909.
23. Gondi V, Tolakanahalli R, Mehta MP, Tewatia D, Rowley H, Kuo JS, et al.
Hippocampal-sparing whole-brain radiotherapy: a “how-to” technique using
helical tomotherapy and linear accelerator-based intensity-modulated
radiotherapy. Int J Radiat Oncol Biol Phys. 2010;78(4):1244–52. doi:10.1016/j.
ijrobp.2010.01.039.
24. Oskan F, Ganswindt U, Schwarz SB, Manapov F, Belka C, Niyazi M.
Hippocampus sparing in whole-brain radiotherapy. A review.
Strahlentherapie Und Onkologie. 2014;190(4):337–41. doi:10.1007/s00066-
013-0518-8.
25. Prokic V, Wiedenmann N, Fels F, Schmucker M, Nieder C, Grosu AL. Whole
brain irradiation with hippocampal sparing and dose escalation on multiple
brain metastases: a planning study on treatment concepts. Int J Radiat
Oncol Biol Phys. 2013;85(1):264–70. doi:10.1016/j.ijrobp.2012.02.036.
26. Marsh JC, Herskovic AM, Gielda BT, Hughes FF, Hoeppner T, Turian J, et al.
Intracranial metastatic disease spares the limbic circuit: a review of 697
metastatic lesions in 107 patients. Int J Radiat Oncol Biol Phys. 2010;76(2):
504–12. doi:10.1016/j.ijrobp.2009.02.038.
27. Wan JF, Zhang SJ, Wang L, Zhao KL. Implications for preserving neural stem
cells in whole brain radiotherapy and prophylactic cranial irradiation: a
review of 2270 metastases in 488 patients. J Radiat Res. 2013;54(2):285–91.
doi:10.1093/jrr/rrs085.
28. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, et al.
Recursive partitioning analysis (RPA) of prognostic factors in three Radiation
Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol
Biol Phys. 1997;37(4):745–51.
Tsai et al. Radiation Oncology  (2015) 10:253 Page 14 of 15
29. Gaspar LE, Scott C, Murray K, Curran W. Validation of the RTOG recursive
partitioning analysis (RPA) classification for brain metastases. Int J Radiat
Oncol Biol Phys. 2000;47(4):1001–6.
30. Castilla-Ortega E, Pedraza C, Estivill-Torrus G, Santin LJ. When is adult
hippocampal neurogenesis necessary for learning? evidence from animal
research. Rev Neurosci. 2011;22(3):267–83. doi:10.1515/RNS.2011.027.
31. Nelson HE. A modified card sorting test sensitive to frontal lobe defects.
Cortex. 1976;12(4):313–24.
32. Wechsler D. Wechsler Adult Intellegence Scale - Third Edition. San Antonio:
Tx. The Psychological Corporation; 1997.
33. Gondi V, Tome WA, Marsh J, Struck A, Ghia A, Turian JV, et al. Estimated risk
of perihippocampal disease progression after hippocampal avoidance
during whole-brain radiotherapy: safety profile for RTOG 0933. Radiother
Oncol. 2010;95(3):327–31. doi:10.1016/j.radonc.2010.02.030.
34. Harth S, Abo-Madyan Y, Zheng L, Siebenlist K, Herskind C, Wenz F, et al.
Estimation of intracranial failure risk following hippocampal-sparing whole
brain radiotherapy. Radiother Oncol. 2013;109(1):152–8. doi:10.1016/j.radonc.
2013.09.009.
35. Eichenbaum H. A cortical-hippocampal system for declarative memory. Nat
Rev Neurosci. 2000;1(1):41–50. doi:10.1038/35036213.
36. Tang SG, Tseng CK, Tsay PK, Chen CH, Chang JW, Pai PC, et al. Predictors for
patterns of brain relapse and overall survival in patients with non-small cell
lung cancer. J Neurooncol. 2005;73(2):153–61. doi:10.1007/s11060-004-3725-4.
37. Barani IJ, Cuttino LW, Benedict SH, Todor D, Bump EA, Wu Y, et al. Neural
stem cell-preserving external-beam radiotherapy of central nervous system
malignancies. Int J Radiat Oncol Biol Phys. 2007;68(4):978–85. doi:10.1016/j.
ijrobp.2007.01.064.
38. Roman DD, Sperduto PW. Neuropsychological effects of cranial radiation:
current knowledge and future directions. Int J Radiat Oncol Biol Phys. 1995;
31(4):983–98. doi:10.1016/0360-3016(94)00550-8.
39. Gutierrez AN, Westerly DC, Tome WA, Jaradat HA, Mackie TR, Bentzen SM, et
al. Whole brain radiotherapy with hippocampal avoidance and
simultaneously integrated brain metastases boost: a planning study. Int J
Radiat Oncol Biol Phys. 2007;69(2):589–97. doi:10.1016/j.ijrobp.2007.05.038.
40. Barani IJ, Benedict SH, Lin PS. Neural stem cells: implications for the
conventional radiotherapy of central nervous system malignancies. Int J
Radiat Oncol Biol Phys. 2007;68(2):324–33. doi:10.1016/j.ijrobp.2007.01.033.
41. Barani IJ, Larson DA, Berger MS. Future directions in treatment of brain
metastases. Surg Neurol Int. 2013;4 Suppl 4:S220–30. doi:10.4103/2152-7806.
111299.
42. Bodensohn R, Soehn M, Ganswindt U, Schupp G, Nachbichler SB, Schnell O,
et al. Hippocampal EUD in primarily irradiated glioblastoma patients. Radiat
Oncol. 2014;9:276. doi:10.1186/s13014-014-0276-5.
43. Niemierko A. Reporting and analyzing dose distributions: A concept of
equivalent uniform dose. Med Phys. 1997;24(1):103–10. doi:10.1118/1.
598063.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Tsai et al. Radiation Oncology  (2015) 10:253 Page 15 of 15
